207.23

0.40% 0.83

After Hours: 207.90 0.67 +0.32%

Cardinal Health Inc (CAH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Cardinal Health Inc stock is traded at $207.23, with a volume of 1.98M. It is up +0.40% in the last 24 hours and down -8.29% over the past month. Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Previous Close:

$206.40

Open:

$206.91

24h Volume:

1.98M

Relative Volume:

1.12

Market Cap:

$48.76B

Revenue:

$244.67B

Net Income/Loss:

$1.68B

P/E Ratio:

29.82

EPS:

6.9487

Net Cash Flow:

$5.51B

1W Performance:

-4.22%

1M Performance:

-8.29%

6M Performance:

+34.06%

1Y Performance:

+55.57%

1-Day Range:

$203.86

$208.72

1-Week Range:

$203.86

$216.21

52-Week Range:

$120.72

$233.60

Cardinal Health Inc Stock (CAH) Company Profile

Name

Cardinal Health Inc

Sector

Healthcare (1113)

Industry

Medical Distribution (11)

Phone

(614) 757-3033

Address

7000 CARDINAL PLACE, DUBLIN, OH

Employee

57,700

Twitter

@cardinalhealth

Next Earnings Date

2024-11-01

Latest SEC Filings

CAH's Discussions on Twitter

Compare CAH vs MCK, COR, HSIC, AHG

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAH Cardinal Health Inc	207.23	48.57B	244.67B	1.68B	5.51B	6.9487
MCK Mckesson Corporation	881.94	107.42B	397.96B	4.55B	9.64B	34.77
COR Cencora Inc	327.27	62.37B	325.78B	1.64B	3.61B	8.3139
HSIC Henry Schein Inc	74.02	8.54B	13.18B	419.00M	521.00M	3.2704
AHG Akso Health Group Adr	2.27	2.06B	14.85M	-136.07M	7.23M	-0.4726

Cardinal Health Inc Stock (CAH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-09-26	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Barclays	Overweight
Jun-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-05-25	Upgrade	Jefferies	Hold → Buy
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Jan-07-25	Upgrade	Evercore ISI	In-line → Outperform
Jan-06-25	Upgrade	BofA Securities	Neutral → Buy
Dec-13-24	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-04-24	Resumed	Mizuho	Outperform
Feb-26-24	Initiated	Leerink Partners	Outperform
Feb-09-24	Upgrade	Argus	Hold → Buy
Jan-03-24	Initiated	Barclays	Overweight
Dec-14-23	Initiated	Wells Fargo	Underweight
Jul-10-23	Downgrade	Evercore ISI	Outperform → In-line
Mar-31-23	Initiated	Citigroup	Neutral
Feb-03-23	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-04-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-22-22	Resumed	Morgan Stanley	Overweight
May-26-22	Downgrade	Barclays	Overweight → Equal Weight
May-18-22	Upgrade	Evercore ISI	In-line → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-01-22	Resumed	Credit Suisse	Neutral
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Aug-05-21	Downgrade	BofA Securities	Buy → Underperform
May-10-21	Downgrade	Robert W. Baird	Outperform → Neutral
Jan-08-21	Upgrade	Wolfe Research	Underperform → Peer Perform
Nov-02-20	Upgrade	Barclays	Equal Weight → Overweight
Sep-25-20	Upgrade	Deutsche Bank	Hold → Buy
Jul-20-20	Upgrade	Guggenheim	Neutral → Buy
May-15-20	Upgrade	UBS	Neutral → Buy
Apr-23-20	Resumed	Credit Suisse	Neutral
Mar-20-20	Upgrade	BofA/Merrill	Underperform → Buy
Feb-12-20	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-07-20	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-16-19	Downgrade	Guggenheim	Buy → Neutral
Sep-12-19	Initiated	Deutsche Bank	Hold
Aug-27-19	Downgrade	Argus	Buy → Hold
Aug-20-19	Upgrade	Guggenheim	Neutral → Buy
Apr-18-19	Initiated	Guggenheim	Neutral
Jan-17-19	Initiated	UBS	Neutral
Nov-16-18	Downgrade	Leerink Partners	Outperform → Mkt Perform
Apr-24-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
Apr-02-18	Upgrade	Argus	Hold → Buy
Mar-08-18	Initiated	Barclays	Equal Weight
Feb-27-18	Resumed	BofA/Merrill	Underperform
Jan-05-18	Initiated	Evercore ISI	In-line

View All

Cardinal Health Inc Stock (CAH) Latest News

02:44 AM

Cardinal Health Inc. stock faces steady trading amid healthcare supply chain shifts and sector headw - AD HOC NEWS

02:44 AM

11:31 AM

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet? - The Globe and Mail

11:31 AM

09:37 AM

Cardinal Health (CAH) Surged Following Improved Specialty Mix in Pharma - Yahoo Finance

09:37 AM

06:45 AM

Cardinal Health sets April 30 webcast for fiscal Q3 results - Stock Titan

06:45 AM

06:42 AM

SG Americas Securities LLC Buys 708,995 Shares of Cardinal Health, Inc. $CAH - MarketBeat

06:42 AM

05:38 AM

Cardinal Health names new board leader following chairman's sudden retirement - The Business Journals

05:38 AM

04:02 AM

Cardinal Health Inc stock faces valuation scrutiny amid board changes and strong analyst support - AD HOC NEWS

04:02 AM

Mar 23, 2026

Cardinal Health (NYSE:CAH) Strengthens Global Network For Russell 1000 Etf Watchers - Kalkine Media

Mar 23, 2026

Cardinal Health, Inc. Files Form 8-K with SEC Detailing Company Information and NYSE Listing - Minichart

Mar 23, 2026

Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock? - TradingView

Mar 23, 2026

[8-K] CARDINAL HEALTH INC Reports Material Event | CAH SEC FilingForm 8-K - Stock Titan

Mar 23, 2026

Cardinal Health turns to longtime director Patricia Hall as chair - Stock Titan

Mar 23, 2026